Department of Urology, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany.
Outpatient Clinic Praxisklinik für Urologie Rhein/Ruhr, Schulstr. 11, 45468, Mülheim an der Ruhr, Germany.
World J Urol. 2020 Jun;38(6):1509-1515. doi: 10.1007/s00345-019-02926-0. Epub 2019 Aug 30.
To evaluate the diagnostic accuracy of a second look narrow-band imaging (NBI) cystoscopy in the follow-up of patients with NMIBC as compared to a second white light cystoscopy (WLI).
From August 2013 to October 2014, 600 patients with history of non-muscle invasive bladder cancer (NMIBC), who presented for follow-up cystoscopy at an academic outpatient clinic, were randomized to flexible WLI-cystoscopy plus second look NBI-cystoscopy (n = 300) or flexible WLI-cystoscopy plus second look WLI-cystoscopy (n = 300) in the same session. We analysed the detection rate of bladder tumours in second look cystoscopy as primary endpoint. In addition, we evaluated recurrence rates before study enrolment and after transurethral resection (TUR-BT) in each group.
In 600 patients with a history of NMIBC, 78 out of 300 patients (26%) with WLI-NBI-cystoscopy and 70 out of 300 patients (23%) with WLI-WLI-cystoscopy were diagnosed with cancer recurrence (p = 0.507). Overall, WLI-NBI detected 404 and WLI-WLI 234 lesions, respectively. The second look cystoscopy detected 57 additional cancer lesions: 45 tumours in 18 patients with WLI-NBI and 12 tumours in 9 patients with WLI-WLI (p = 0.035). After initial examination without tumour detection an improvement was determined by the second cystoscopy in 3 patients (75 vs. 78 pat.) with WLI-NBI and in only one patient (69 vs. 70 pat.) with WLI-WLI (p = 0.137). Second look cystoscopy did not influence the detection of carcinoma in situ in both groups (p = 0.120). After TUR-BT the median recurrence-free survival was 4 months in 57 recurring patients (73%) in the group with WLI-NBI- and 6 months in 56 patients (80%) with WLI-WLI-cystoscopy (p = 0.373), respectively.
Our study showed no differences in per-patient tumour detection between WLI and NBI. Although NBI has significant benefits for detecting individual lesions overlooked by WLI-cystoscopy, this did not positively affect recurrence-free survival after transurethral resection.
评估在非肌层浸润性膀胱癌(NMIBC)患者的随访中,与第二次白光膀胱镜检查(WLI)相比,第二次窄带成像(NBI)膀胱镜检查的诊断准确性。
2013 年 8 月至 2014 年 10 月,在一家学术门诊就诊的 600 例非肌层浸润性膀胱癌患者被随机分为两组,一组接受柔性 WLI 膀胱镜检查加第二次 NBI 膀胱镜检查(n=300),另一组接受柔性 WLI 膀胱镜检查加第二次 WLI 膀胱镜检查(n=300)。我们分析了第二次膀胱镜检查的膀胱肿瘤检出率作为主要终点。此外,我们还评估了每组在研究入组前和经尿道膀胱肿瘤切除术(TUR-BT)后的复发率。
在 600 例有 NMIBC 病史的患者中,300 例接受 WLI-NBI 膀胱镜检查的患者中有 78 例(26%)和 300 例接受 WLI-WLI 膀胱镜检查的患者中有 70 例(23%)被诊断为癌症复发(p=0.507)。总体而言,WLI-NBI 检测到 404 个病变,WLI-WLI 检测到 234 个病变。第二次膀胱镜检查共检测到 57 个额外的癌症病变:WLI-NBI 中有 18 名患者的 45 个肿瘤和 WLI-WLI 中有 9 名患者的 12 个肿瘤(p=0.035)。在初始检查未发现肿瘤的情况下,WLI-NBI 组中有 3 名患者(75 比 78 例)和 WLI-WLI 组中有 1 名患者(69 比 70 例)的第二次膀胱镜检查发现了改善(p=0.137)。第二次膀胱镜检查对两组原位癌的检出均无影响(p=0.120)。在 TUR-BT 后,WLI-NBI 组中有 57 例复发患者(73%)和 WLI-WLI 组中有 56 例复发患者(80%)的无复发生存中位数分别为 4 个月和 6 个月(p=0.373)。
我们的研究显示,WLI 和 NBI 组在每位患者的肿瘤检出率方面没有差异。尽管 NBI 对检测 WLI 膀胱镜检查漏诊的单个病变有显著优势,但这并没有对 TUR-BT 后的无复发生存率产生积极影响。